Dexamethasone phosphate disodium, a glucocorticoid receptor agonist, is recognized for its oral activity and potent anti-inflammatory effects[1].
Dexamethasone phosphate disodium/地塞米松磷酸钠 动物研究
Animal study
In an experimental model, a dose of 2×5 mg/kg of Dexamethasone phosphate disodium effectively curbs lipopolysaccharide (LPS)-induced inflammation. A single dose of 10 mg/kg administered intraperitoneally significantly reduces the recruitment of granulocytes and the spontaneous production of oxygen radicals in comparison to animals exposed to LPS and treated with saline alone. The treatment is significantly effective both 1 hour before and after LPS inhalation, lowering the number of granulocytes in bronchoalveolar lavage fluid (BALF) to levels comparable to those in healthy animals exposed to an aerosol of water[3].In studies involving rats, those treated with Dexamethasone phosphate disodium exhibited reduced food consumption and body weight compared to controls. Interestingly, these rats also weighed less than pair-fed animals despite having similar food intakes. Five days of treatment with Dexamethasone phosphate disodium led to significant increases in liver mass (by 42%) and the liver to body weight ratio (by 65%). Meanwhile, the wet weight of the gastrocnemius muscle decreased by 20% after 5 days of treatment, but this reduction was proportional to the overall body weight loss, suggesting that muscle weight loss paralleled the general reduction in body weight[4].
搜索
